Take a Trip With Kayak, Skip Durata
Kayak Software should ride the wave of travel site success, but Durata Therapeutics could stumble says Francis Gaskins of IPO Desktop.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.
